ABSTRACT Glucagon-like peptide 1 (GLP-1) is a target for treatment of diabetes; however,
its function in the brain is not well studied. In this systematic review, we aimed to analyze the …

Cognitive impairment is a shared abnormality between type 2 diabetes mellitus (T2DM) and
many neurodegenerative and neuropsychiatric disorders, such as Alzheimer's disease (AD) …

Cannabidiol (CBD), a phytocannabinoid compound, presents antidepressant and anxiolytic-
like effects in the type-1 diabetes mellitus (DM1) animal model. Although the underlying …

Previous investigations have shown that REM sleep deprivation impairs the hippocampus‐
dependent memory, long-term potentiation and causing mood changes. The aim of the …

Evidence supports a strong bidirectional association between depression and Type 2
diabetes mellitus (T2DM). The harmful impact of oxidative stress and chronic inflammation …

Aims/hypothesis We have previously shown that diabetes causes pericyte dysfunction,
leading to loss of vascular integrity and vascular cognitive impairment and dementia (VCID) …

Abstract Glucagon-like peptide-1 (GLP-1) is a multifunctional polypeptide throughout the
lifespan via activating Glucagon-like peptide-1 receptor (GLP-1R). GLP-1 can affect food …

Background Both depression itself and antidepressant medication have been reported to be
significantly related to the risk of type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 …

Diabetic encephalopathy is related to serious damage to the Central Nervous System
leading to several disturbances in memory processing and emotions. It is known that the …

Abstract Aim Exendin-4, a glucagon-like peptide-1 (GLP-1) analog, has been used for
treating diabetes mellitus (DM). However, its effects on improving the dysfunction of high …